Skip to main content

Table 1 Level of evidence and strength of recommendation for RSV prophylaxis with palivizumab

From: Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)

  Level of evidence
I evidence obtained by randomized controlled clinical studies and/or by systematic reviews of randomized studies
II evidence obtained from an individual and adequately designed randomized study
III evidence obtained by cohort studies with concurrent or historical controls, or a meta-analysis thereof.
IV evidence obtained by retrospective, case-controlled studies or meta-analysis
V evidence obtained from case-series studies without a control group
VI evidence based on the opinion of authoritative experts or of committees of experts as indicated in guidelines or a consensus conference, or based on the opinion of the members of the workgroup responsible for this guideline
  Strength of recommendations
A the performance of that particular procedure or diagnostic test is strongly recommended (it indicates a particular recommendation supported by good quality albeit not necessarily type I or II scientific evidence)
B there is some doubt that the procedure/intervention must be always recommended, but it is thought that its execution has to attentively be considered
C there is substantial uncertainty in favor of or against the recommendation to perform the procedure or the intervention
D performing the procedure is not recommended
E performing the procedure is strongly discouraged